Literature DB >> 10021295

Characterization of human ovarian carcinomas in a SCID mouse model.

Y Xu1, D F Silver, N P Yang, E Oflazoglu, R E Hempling, M S Piver, E A Repasky.   

Abstract

This study characterizes a murine model which is promising for the study of the growth and natural history of ovarian cancer and for testing of new therapies for its treatment. Intact portions of 20 different human ovarian cancer surgical specimens were implanted in over 60 severe combined immunodeficient (SCID) mice using techniques previously developed in our laboratory. Growth of xenografts was evaluated by gross examination and histopathologic analysis. Confirmation of the human origin of the tumor outgrowth was obtained using in situ hybridization analysis. By histological evaluation, all of the patients' tumors showed evidence of invasive growth in at least 1 of the mice implanted with portions of each surgical specimen and these tumors remained morphologically similar to the parent tumors for a long period of time. Furthermore, 65% (13/20) of the xenografts grew rapidly enough (i.e., reached a diameter of 1-2 cm within 2-6 months) to allow passage to subsequent SCID mice. Among the passaged xenografts, 3 eventually developed metastases in a distribution pattern similar to that of naturally occurring ovarian cancer and 2 developed ascites without evidence of further metastatic spread. Upon evaluation of sera from tumor-bearing mice, human antibodies presumably derived from immunoglobulin-secreting cells present in the original tumor specimen were identified. In support of this, human B cells and plasma cells could be seen within the tumor xenograft for more than 6 months following implantation. In summary, transplantation of surgical specimens from ovarian cancer patients into SCID mice results in an attractive model for the study of the natural history of ovarian cancer and may also be useful for analysis or new experimental therapeutic approaches for the treatment of this disease. Copyright 1999 Academic Press.

Entities:  

Mesh:

Year:  1999        PMID: 10021295     DOI: 10.1006/gyno.1998.5238

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  24 in total

1.  Tumorgrafts as in vivo surrogates for women with ovarian cancer.

Authors:  S John Weroha; Marc A Becker; Sergio Enderica-Gonzalez; Sean C Harrington; Ann L Oberg; Matthew J Maurer; Sarah E Perkins; Mariam AlHilli; Kristina A Butler; Sarah McKinstry; Stephanie Fink; Robert B Jenkins; Xiaonan Hou; Kimberly R Kalli; Karin M Goodman; Jann N Sarkaria; Beth Y Karlan; Amanika Kumar; Scott H Kaufmann; Lynn C Hartmann; Paul Haluska
Journal:  Clin Cancer Res       Date:  2014-01-07       Impact factor: 12.531

Review 2.  Epithelial ovarian cancer experimental models.

Authors:  E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

Review 3.  Mouse models of myelodysplastic syndromes.

Authors:  Sarah H Beachy; Peter D Aplan
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

4.  An orthotopic model of platinum-sensitive high grade serous fallopian tube carcinoma.

Authors:  Dineo Khabele; Oluwole Fadare; Annie Y Liu; Andrew J Wilson; Erika Wass; Kevin Osteen; Marta A Crispens
Journal:  Int J Clin Exp Pathol       Date:  2011-01-01

5.  Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model.

Authors:  Sandra J Yokota; John G Facciponte; Raymond J Kelleher; Leonard D Shultz; Jenni L Loyall; Robert R Parsons; Kunle Odunsi; John G Frelinger; Edith M Lord; Scott A Gerber; Sathy V Balu-Iyer; Richard B Bankert
Journal:  Cancer Immun       Date:  2013-05-31

Review 6.  Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review.

Authors:  Ketao Jin; Lisong Teng; Yanping Shen; Kuifeng He; Zhenzhen Xu; Guangliang Li
Journal:  Clin Transl Oncol       Date:  2010-07       Impact factor: 3.405

7.  Humoral hypercalcemia of malignancy: severe combined immunodeficient/beige mouse model of adult T-cell lymphoma independent of human T-cell lymphotropic virus type-1 tax expression.

Authors:  V Richard; M D Lairmore; P L Green; G Feuer; R S Erbe; B Albrecht; C D'Souza; E T Keller; J Dai; T J Rosol
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

8.  Anti-tumor effects of adenovirus containing human growth hormone sequences in a mouse model of human ovarian cancer.

Authors:  Yonglian Zhu; José B Fariña; Syrus Meshack; Ana Santoveña; Shilpa Patel; Alexis Oliva; Matias Llabrés; Michael E Hodsdon; Carmen J Booth; Priscilla S Dannies
Journal:  Endocrine       Date:  2010-04-20       Impact factor: 3.633

9.  Influence of the implantation site on the sensitivity of patient pancreatic tumor xenografts to Apo2L/TRAIL therapy.

Authors:  Rohit Sharma; Sandra Buitrago; Rose Pitoniak; John F Gibbs; Leslie Curtin; Mukund Seshadri; Elizabeth A Repasky; Bonnie L Hylander
Journal:  Pancreas       Date:  2014-03       Impact factor: 3.327

10.  AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.

Authors:  David Pépin; Amanda Sosulski; Lihua Zhang; Dan Wang; Vinod Vathipadiekal; Katherine Hendren; Caroline M Coletti; Aaron Yu; Cesar M Castro; Michael J Birrer; Guangping Gao; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.